Aura Biosciences' Belzupacap Sarotalocan At Par With Plaque Radiotherapy In Eye Cancer

Aura Biosciences Inc AURA reported data from a retrospective analysis that assessed the visual acuity after plaque radiotherapy treatment compared with prospective data in early-stage choroidal melanoma patients treated with belzupacap sarotalocan by intravitreal administration in the Phase 1b/2 trial.
The vision results of patients with early-stage choroidal melanoma treated with radiotherapy showed the long-term, progressive, and irreversible loss of visual acuity in patients with tumors near the fovea.
The loss of vision in radiotherapy patients was ≥3 lines in most patients as early as 2 years and ≥6 lines as early as 3 years.
The findings of this retrospective study were consistent with published clinical data supporting the irreversible loss of visual acuity after treatment with radiotherapy.
Due to the retrospective nature of this analysis, it is hypothesis-generating. Hence no formal conclusions can be drawn.
Aura has also initiated a prospective matched case-control study to further evaluate the long-term visual acuity of belzupacap sarotalocan from the Phase 2 trial AU-011-202 using suprachoroidal administration versus radiotherapy.
Price Action: AURA shares are up 10.11% at $14.49 during the premarket session on the last check Thursday.